↓ Skip to main content

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes Influence of prior antidiabetic drug regimen

Overview of attention for article published in Journal of Diabetes & its Complications, July 2003
Altmetric Badge

Mentioned by

patent
16 patents

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes Influence of prior antidiabetic drug regimen
Published in
Journal of Diabetes & its Complications, July 2003
DOI 10.1016/s1056-8727(03)00005-9
Pubmed ID
Authors
Abstract

To evaluate two trials of combination therapy, pioglitazone together with metformin or sulfonylurea, for Type 2 diabetes mellitus and to examine how pretrial antidiabetic therapies may have influenced the results. The results of two published trials that examine combination therapy, pioglitazone plus metformin or pioglitazone plus sulfonylurea were analyzed. A post hoc analysis was performed in which patients from both of these trials were subdivided on the basis of their oral antidiabetic therapy before enrollment into the trials. Those subsets receiving pretrial therapy with a sulfonylurea plus metformin - and discontinuing one of the agents before randomization - were compared to those receiving only one of the agents before enrollment. Patients in the combination pioglitazone (30 mg/day) plus metformin therapy arm of one trial, who entered with stable metformin monotherapy, experienced a significant decrease in glycosylated hemoglobin (HbA(1C)) levels during the 16-week course of the trial (-1.0+/-0.1 [mean+/-S.E.] percentage points; P<.05). In contrast, those in the same arm of the trial whose pretrial therapy included metformin plus a sulfonylurea - and who discontinued the sulfonylurea before enrollment - experienced no significant change in HbA(1C) levels (0.2+/-0.2 percentage points; P>.05). The difference between groups was significant (P<.001). Patients in the combination pioglitazone (15 or 30 mg/day) plus sulfonylurea therapy arm of the other trial, who entered the trial on stable sulfonylurea monotherapy, experienced significant decreases in HbA(1C) levels (-1.0+/-0.1 and -1.4+/-0.1 percentage points, respectively, for the 15- and 30-mg pioglitazone arms; P<.05). Those in the same arm whose pretrial therapy included sulfonylurea plus metformin - and who discontinued the metformin before enrollment - experienced no significant change in HbA(1C) levels. Differences between the groups separated on the basis of pretrial antidiabetic regimen were significant (P<.001). The efficacy of pioglitazone as an add-on in combination therapy (with metformin or a sulfonylurea) is likely to be greater than in previous reports, because those trial results were influenced by treatment regimens used by a portion of the patients before enrollment. Trials of oral hypoglycemic agents must be carefully constructed to consider the effects of agents given prior to the trial.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Brazil 1 3%
Unknown 33 97%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Other 6 18%
Student > Doctoral Student 4 12%
Student > Bachelor 4 12%
Student > Master 4 12%
Researcher 4 12%
Other 3 9%
Unknown 9 26%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 12 35%
Agricultural and Biological Sciences 6 18%
Nursing and Health Professions 4 12%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 0 0%
Unknown 10 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2014.
All research outputs
#12,428,062
of 34,526,284 outputs
Outputs from Journal of Diabetes & its Complications
#702
of 1,658 outputs
Outputs of similar age
#33,798
of 76,389 outputs
Outputs of similar age from Journal of Diabetes & its Complications
#2
of 4 outputs
Altmetric has tracked 34,526,284 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,658 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,389 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.